Evidence map›Paper›PMID 32081787›Full record

Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2020

Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts.

Omid Shah, John S Tamaresis, Laura Jean Kenyon, Liwen Xu, Pingping Zheng, Puja Gupta, Krish Rangarajan, Stephanie Lee, Stephen Spellman, Sarah Nikiforow and 2 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01002742 (A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01002742 phase3completednot on this map

A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)

TypeinterventionalSponsorMedical College of WisconsinRan2010 to 2013Enrolled236ConditionsGraft-versus-Host Disease, Immune System DisordersArmsMycophenolate Mofetil, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Healthy-like CD4International journal of molecular sciences · 2022
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Omid ShahDivision of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California.
John S TamaresisDepartment of Biomedical Data Science, Stanford University School of Medicine, Stanford, California.
Laura Jean KenyonDivision of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California.
Liwen XuDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Pingping ZhengDivision of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California.
Puja GuptaDivision of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California.
Krish RangarajanDivision of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California.
Stephanie LeeFred Hutchinson Cancer Research Center, Seattle, Washington.
Stephen SpellmanNational Marrow Donor Program/C Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
Sarah NikiforowDana-Farber Cancer Institute, Boston, Massachusetts.
James ZehnderDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Everett H MeyerDivision of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California. Electronic address: evmeyer@stanford.edu.
Stanford University · USDana-Farber Cancer Institute · USFred Hutch Cancer Center · USNational Marrow Donor Program · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
TUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos · 1989 to 2026
$73.3M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
TLI/ATG CONDTIONING: KIDNEY/BLOOD STEM CELL TRANSPLANTSP01HL075462 · NHLBI · STANFORD UNIVERSITY · PI ENGLEMAN, EDGAR G. · 2004 to 2020
$27.9M
T-cell monitoring and immunotherapy for treating graft-versus-host diseaseK08HL119590 · NHLBI · STANFORD UNIVERSITY · PI MEYER, EVERETT · 2014 to 2018
$767k
NCI NIH HHS P01 CA049605NCI NIH HHS U24 CA076518NHLBI NIH HHS K08 HL119590NHLBI NIH HHS P01 HL075462NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U24 HL138660
6 · The paper itself

Abstract

A major cause of morbidity and mortality for patients who undergo hematologic stem cell transplantation (HSCT) is acute graft-versus-host disease (aGVHD), a mostly T cell-mediated disease. Examination of the T cell receptor (TCR) repertoire of HSCT recipients and the use of next-generation nucleotide sequencing have raised the question of whether features of TCR repertoire reconstitution might reproducibly associate with aGVHD. We hypothesized that the peripheral blood TCR repertoire of patients with steroid-nonresponsive aGVHD would be less diverse. We also hypothesized that patients with GVHD who shared HLA might also share common clones at the time of GVHD diagnosis, thereby potentially providing potential clinical indicators for treatment stratification. We further hypothesized that HSCT recipients with the same HLA mismatch might share a more similar TCR repertoire based on a potentially shared focus of alloreactive responses. We studied 2 separate patient cohorts and 2 separate platforms for measuring TCR repertoire. The first cohort of patients was from a multicenter Phase III randomized double-blinded clinical trial of patients who developed aGVHD (NCT01002742). The second cohort comprised samples from biobanks from 2 transplantation centers and the Center for International Blood and Marrow Transplant Research of patients who underwent mismatched HSCT. There were no statistically significant differences in the TCR diversity of steroid responders and nonresponders among patients with aGVHD on the day of diagnosis. Most clones in the repertoire were unique to each patient, but a small number of clones were found to be both exclusive to and shared among aGVHD nonresponders. We were also able to show a strong correlation between the presence of Vβ20 and Vβ29 and steroid responsiveness. Using the Bhattacharya coefficient, those patients who shared the same HLA mismatch were shown to be no more similar to one another than to those who had a completely different mismatch. Using 2 separate clinical cohorts and 2 separate platforms for analyzing the TCR repertoire, we have shown that the sampled human TCR repertoire is largely unique to each patient but contains glimmers of common clones of subsets of clones based on responsiveness to steroids in aGVHD on the day of diagnosis. These studies are informative for future strategies to assess for reproducible TCR responses in human alloreactivity and possible markers of GVHD responsiveness to therapy.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationClone CellsHumansReceptors, Antigen, T-CellT-LymphocytesReceptors, Antigen, T-CellCDR3Graft-versus-host diseaseStem cell transplantationT cellT-cell receptor

Identifiers

PMID32081787
PMCPMC7503214
OpenAlexW3008081993

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.